ES2584161T3 - Uso de dimiracetam en el tratamiento del dolor crónico - Google Patents
Uso de dimiracetam en el tratamiento del dolor crónico Download PDFInfo
- Publication number
- ES2584161T3 ES2584161T3 ES14004202.9T ES14004202T ES2584161T3 ES 2584161 T3 ES2584161 T3 ES 2584161T3 ES 14004202 T ES14004202 T ES 14004202T ES 2584161 T3 ES2584161 T3 ES 2584161T3
- Authority
- ES
- Spain
- Prior art keywords
- dimiracetam
- treatment
- chronic pain
- test
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002193 Pain Diseases 0.000 title abstract description 4
- XTXXOHPHLNROBN-UHFFFAOYSA-N dimiracetam Chemical compound N1C(=O)CN2C1CCC2=O XTXXOHPHLNROBN-UHFFFAOYSA-N 0.000 title abstract description 4
- 229950002911 dimiracetam Drugs 0.000 title abstract description 4
- 208000000094 Chronic Pain Diseases 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 229940124977 antiviral medication Drugs 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Dimiracetam, o uno de sus solvatos farmacéuticamente aceptables, para su uso en el tratamiento y/o la prevención del dolor crónico inducido por un medicamento antitumoral o antiviral, en el que el dimiracetam se administra solo o en asociación con dicho medicamento antitumoral o antiviral.
Description
para su uso en el tratamiento en cuestión.
A continuación se proporcionan ejemplos de la presente invención, puramente con fines ilustrativos.
1. MÉTODOS
1.1 Neuropatía periférica inducida por quimioterapia (CIPN)
10 La neuropatía periférica se induce por la administración repetida de vincristina, taxol u oxaliplatino a ratas macho adultas Sprague-Dawley (150-200 g, proveedor Harlan).
Se utilizaron respectivamente los siguientes protocolos: 15
• Vincristina: el fármaco se inyectó por vía intravenosa a una dosis de 150 μg/kg. El tratamiento se realizó cada 2 días, 5 veces, hasta que se alcanzó una dosis acumulada de 750 μg/kg. Se realizó la prueba de presión de la pata 4 días después de la última inyección (Marchand F. et al., 2003, Brain Res 980: 117-120).
20 • Taxol: se indujo neuropatía con taxol mediante la administración intraperitoneal de 0,5 mg/kg una vez al día, los días 1, 3, 5 y 8. La dosis acumulada de taxol era de 2 mg/kg. Se realizó la prueba farmacológica 14-18 días después de la última inyección de taxol (Polomano R.C. et al., 2001, Pain 94: 293-304).
• Oxaliplatino: se inyectaron 2,4 mg/kg por vía intraperitoneal durante 5 días consecutivos, seguido de 2 días de
25 suspensión (un ciclo). Se realizó un total de 3 ciclos, hasta alcanzar una dosis acumulada de 36 mg/kg (Cavaletti G. 2001, Eur J. Cancer 37: 2457-2463). La prueba se realizó 48 h después de la última inyección de oxaliplatino.
30 Ratas macho adultas Sprague Dawley (150-200 g, proveedor Harlan) se trataron por vía intravenosa con una administración única de 25 mg/kg de inhibidores de la transcriptasa inversa análogos de nucleósidos ddC (2',3'didesoxicitidina) o d4T (2',3'-dideshidro-3'-desoxitimidina). La administración de estos fármacos anti-VIH induce una marcada respuesta alodínica a un estímulo mecánico (Joseph E.K. 2004, Pain 107: 147-158). Se desarrolla la máxima reducción del umbral de presión de la pata entre el día 5 y el día 10 después de la inyección. La prueba se
35 realizó el día 10.
La hiperalgesia mecánica en ratas (ratas macho adultas Sprague Dawley, 150-200 g, proveedor Harlan) se
40 determinó mediante la prueba de presión de la pata. El umbral nociceptivo se determinó con un analgesímetro (Ugo Basile, Italia), que ejerce una fuerza que aumenta a una velocidad constante (32 g/s) de acuerdo con el método descrito por Leighton G.E. 1988, Br. J. Pharmacol. 93: 553-560. El estímulo que causa la retirada de la pata se evaluó antes y a diferentes momentos después del tratamiento. Los resultados representan la media de los umbrales mecánicos expresados en gramos. Para evitar cualquier posible daño a la pata del animal la fuerza máxima aplicada
45 se fijó en 240 g.
Las ratas (ratas macho adultas Sprague Dawley, 150-200 g, proveedor Harlan) se pusieron en una cámara con un
50 suelo de malla metálica cubierta por una cúpula de plástico que permitía que los animales caminen libremente, pero que no puedan saltar. El estímulo mecánico se produjo sobre la piel en el medio de la planta de la pata trasera izquierda utilizando un aparato electrónico de von Frey. El punto de corte se fijó en 50 g, mientras que la tasa de aumento de la fuerza (duración de la rampa) se estableció a 20 s.
Para comprobar si la administración del compuesto puede inducir efectos secundarios mediados centralmente, ratas macho adultas Sprague Dawley (150-200 g, proveedor Harlan) se trataron con dimiracetam por vía subcutánea y oral y se evaluaron de acuerdo con el protocolo de la "prueba de Irwin" (Irwin 1968, Psychopharmacologia 13: 222
7
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000770A ITMI20070770A1 (it) | 2007-04-16 | 2007-04-16 | Impiego di dimiracetam nel trattamento del dolore cronico |
| ITMI20070770 | 2007-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2584161T3 true ES2584161T3 (es) | 2016-09-26 |
Family
ID=39628738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14004202.9T Active ES2584161T3 (es) | 2007-04-16 | 2008-04-15 | Uso de dimiracetam en el tratamiento del dolor crónico |
| ES08749565.1T Active ES2536631T3 (es) | 2007-04-16 | 2008-04-15 | Uso de dimiracetam en el tratamiento de dolor crónico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08749565.1T Active ES2536631T3 (es) | 2007-04-16 | 2008-04-15 | Uso de dimiracetam en el tratamiento de dolor crónico |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7989421B2 (es) |
| EP (3) | EP2620149A3 (es) |
| JP (1) | JP5409602B2 (es) |
| CN (2) | CN101677984A (es) |
| AU (1) | AU2008237901B2 (es) |
| BR (1) | BRPI0810475A2 (es) |
| CA (1) | CA2684363C (es) |
| EA (2) | EA022867B1 (es) |
| ES (2) | ES2584161T3 (es) |
| IL (2) | IL201498A (es) |
| IT (1) | ITMI20070770A1 (es) |
| MX (1) | MX2009011380A (es) |
| PL (2) | PL2857017T3 (es) |
| WO (1) | WO2008125674A1 (es) |
| ZA (1) | ZA200906991B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
| WO2012013640A1 (en) | 2010-07-26 | 2012-02-02 | Neurotune Ag | Process for the preparation of dimiracetam |
| CA2828238A1 (en) * | 2010-10-29 | 2012-05-03 | Neurotune Ag | Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib |
| WO2012137645A1 (ja) * | 2011-04-07 | 2012-10-11 | 旭化成ファーマ株式会社 | 抗癌剤に起因する異痛症の予防及び／又は治療剤 |
| CN102743372B (zh) * | 2012-06-30 | 2015-09-09 | 江苏省中医药研究院 | 一种化疗致血痹动物模型建立方法 |
| JOP20190251A1 (ar) | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
| CA3082295A1 (en) * | 2017-11-21 | 2019-05-31 | Medoncare Pharmaceutical Co., Ltd | Combination products containing dicycloplatin, preparation and use thereof |
| DE102019107619A1 (de) | 2019-03-25 | 2020-10-01 | Mondi Ag | Verpackungsbeutel aus einem Kunststoffgewebeverbund |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3324219A1 (de) * | 1983-07-05 | 1985-01-17 | Hoechst Ag, 6230 Frankfurt | Mehrlagige elektroisolierfolie |
| US5028595A (en) * | 1987-09-18 | 1991-07-02 | Hoffmann-La Roche Inc. | Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus |
| IT1233860B (it) | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
| GB9123641D0 (en) | 1991-11-07 | 1992-01-02 | Isf Spa | Process |
| BR0015974A (pt) * | 1999-12-01 | 2002-07-23 | Ucb Sa | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto |
| WO2002053153A1 (en) * | 2000-12-28 | 2002-07-11 | Daiichi Pharmaceutical Co., Ltd. | Medicines for treatment and prevention of neurogenic pain |
| ITMI20030573A1 (it) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
-
2007
- 2007-04-16 IT IT000770A patent/ITMI20070770A1/it unknown
-
2008
- 2008-04-15 EP EP13002151.2A patent/EP2620149A3/en not_active Withdrawn
- 2008-04-15 BR BRPI0810475A patent/BRPI0810475A2/pt not_active IP Right Cessation
- 2008-04-15 PL PL14004202.9T patent/PL2857017T3/pl unknown
- 2008-04-15 AU AU2008237901A patent/AU2008237901B2/en not_active Ceased
- 2008-04-15 EP EP08749565.1A patent/EP2146706B1/en active Active
- 2008-04-15 ES ES14004202.9T patent/ES2584161T3/es active Active
- 2008-04-15 PL PL08749565T patent/PL2146706T3/pl unknown
- 2008-04-15 CA CA2684363A patent/CA2684363C/en not_active Expired - Fee Related
- 2008-04-15 EA EA201300826A patent/EA022867B1/ru not_active IP Right Cessation
- 2008-04-15 ES ES08749565.1T patent/ES2536631T3/es active Active
- 2008-04-15 US US12/450,944 patent/US7989421B2/en active Active
- 2008-04-15 MX MX2009011380A patent/MX2009011380A/es active IP Right Grant
- 2008-04-15 EP EP14004202.9A patent/EP2857017B1/en active Active
- 2008-04-15 CN CN200880015837A patent/CN101677984A/zh active Pending
- 2008-04-15 JP JP2010503482A patent/JP5409602B2/ja active Active
- 2008-04-15 WO PCT/EP2008/054553 patent/WO2008125674A1/en not_active Ceased
- 2008-04-15 CN CN201310182360.3A patent/CN103284997B/zh not_active Expired - Fee Related
- 2008-04-15 EA EA200901237A patent/EA019354B1/ru not_active IP Right Cessation
-
2009
- 2009-10-07 ZA ZA2009/06991A patent/ZA200906991B/en unknown
- 2009-10-13 IL IL201498A patent/IL201498A/en active IP Right Grant
-
2011
- 2011-06-22 US US13/166,088 patent/US8222241B2/en active Active
-
2012
- 2012-03-26 IL IL218851A patent/IL218851A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2584161T3 (es) | Uso de dimiracetam en el tratamiento del dolor crónico | |
| MX2020003462A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| JP2015110588A5 (es) | ||
| MX2020003421A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| ATE511392T1 (de) | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MX2010003642A (es) | Nanotecnologia de vacuna. | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| MX388482B (es) | Métodos para tratar el virus de la hepatitis c. | |
| JP2012533565A5 (es) | ||
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| FI3044229T3 (fi) | Peptidejä käytettäväksi suun limakalvotulehduksen hoidossa | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| ES2663836T3 (es) | Carboxamidas de quinolina para su uso en el tratamiento de leucemia | |
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| FI3442538T3 (fi) | Levodopan aiheuttaman dyskinesian hoito trapidiililla | |
| ES2563068T3 (es) | Tratamiento de esclerosis múltiple (MS) con Campath-1H | |
| WO2019147338A3 (en) | Radiopharmaceuticals and methods of use thereof | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon |